Home - Products-JKN Signaling Pathways-Iptacopan HCl

Iptacopan HCl

CAS:

1646321-63-2

Cat No:

JKN00081

Purity:

98%

Inquire Now + Next Product +

Note: All products of the company are for scientific research only, and do not provide products and services for any individual

Iptacopan Hydrochloride — Orally Bioavailable Factor B Inhibitor

Iptacopan hydrochloride (also known as LNP023 HCl) is a highly potent, orally bioavailable complement Factor B inhibitor with excellent selectivity and high affinity binding, widely used in complement pathway research, drug discovery, and mechanistic studies targeting complement‑mediated diseases. JKN Biochem supplies high‑purity Iptacopan HCl suitable for pharmaceutical R&D, CRO procurement, and advanced laboratory applications.

Key Features & High‑Purity Research Benefits

● Orally bioavailable small molecule with potent inhibitory activity against complement Factor B (IC₅₀ ~ 10 nM)

● High affinity binding (KD ~7.9 nM) with excellent selectivity over other proteases in vitro and in vivo

● Essential research compound for complement system studies, including paroxysmal nocturnal hemoglobinuria (PNH), IgA nephropathy, and C3 glomerulopathy

● Supplied in multiple quantities with stringent quality control (purity ≥98%) to meet lab and pharma procurement needs

Mechanism of Action (MoA)

Iptacopan HCl selectively targets complement Factor B, inhibiting its activity in the alternative complement cascade. By blocking the formation of the C3 convertase complex, Iptacopan effectively suppresses downstream complement activation, providing a valuable tool for investigating complement‑mediated hemolysis and inflammatory responses in disease models. This targeted inhibition makes it ideal for complement research and therapeutic evaluation.

Pharmacological Insights & Research Applications

As a small molecule proximal complement inhibitor, Iptacopan demonstrates:

● Oral bioavailability and rapid absorption in preclinical models

● Specific inhibition of Factor B with nominal off‑target effects across protease panels

● Effective modulation of biomarkers linked to complement activation in experimental systems

Why Choose JKN Biochem for Iptacopan HCl?

● Global B2B supplier of high‑quality research compounds and APIs

● Flexible supply options from mg to multi‑gram and bulk quantities

● Strict QC standards with full batch documentation

● Responsive technical support and reliable international logistics

Product Description

CAS	1646321-63-2	Cat No	JKN00081
Name	Iptacopan HCl
Synonyms	LNP023
Smiles	O=C(O)C1=CC=C([C@H]2N(CC3=C(OC)C=C(C)C4=C3C=CN4)CC[C@H](OCC)C2)C=C1.[H]Cl
Chemical Name	4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid hydrochloride
Formula	C25H31ClN2O4	MWt	458.980
Purity	98%	Storage	Store at 4--8℃
Description	Iptacopan, also known as LNP023, is a complement Factor B Inhibitor (IC50=10 nM). LNP023 improves LN in MRL/lpr mice. The mechanism is as follows: LNP023 binds to CFB to inhibit the activation of the alternative complement pathway. LNP023 treatment for LN may also play a role in regulating the protein expression of AKT, TNF-α, and STST3. LNP023 showed low clearance and high bioavailability (62.2%). Furthermore, four minor metabolites from rat plasma were detected and identified by LC combined with high-resolution mass spectrometry. The metabolic pathways were O-deethylation (M1), hydroxylation (M4), oxidation (M3), and acyl-glucuronidation (M2).

Product Documents

Products Category